ACM
IBB icon

Arlington Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Arlington Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,875
Closed -$211K – 24
2015
Q4 		$211K Sell
1,875
-3,324
-64% -$361K 0.25% 16
2015
Q3 		$526K Sell
5,199
-174,993
-97% -$21M 0.64% 11
2015
Q2 		$22.5M Buy
180,192
+18,009
+11% +$2.16M 15.05% 1
2015
Q1 		$18.6M Buy
162,183
+12,675
+8% +$1.4M 13.29% 1
2014
Q4 		$15.1M Buy
+149,508
New +$14.5M 12.79% 1

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Arlington Capital Management's IBB Position: Q1 2016 in Review

Arlington Capital Management sold out of iShares Biotechnology ETF (IBB) in Q1 2016, closing a stake of 1,875 shares — an estimated $211K sold.

Arlington Capital Management first reported a position in IBB in Q4 2014 and held it in 5 quarters. The position peaked at $22.5M in Q2 2015. 415 funds tracked by Wall St. Rank hold IBB as of Q1 2016.

  • Arlington Capital Management reported no remaining iShares Biotechnology ETF position as of Q1 2016 after selling out during the quarter.
  • Arlington Capital Management sold 1,875 iShares Biotechnology ETF shares in Q1 2016, an estimated $211K.
  • Arlington Capital Management first reported a position in iShares Biotechnology ETF in Q4 2014 and held it in 5 quarters.
  • Arlington Capital Management's iShares Biotechnology ETF position peaked at $22.5M in Q2 2015.
  • 415 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2016.

Based on Arlington Capital Management's 13F filing for Q1 2016, filed 3 May 2016.